PTC THERAPEUTICS INC's ticker is PTCT and the CUSIP is 69366J200. A total of 65 filers reported holding PTC THERAPEUTICS INC in Q1 2014. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,191,029 | -55.5% | 187,016 | -19.3% | 0.82% | -48.1% |
Q2 2023 | $9,423,076 | -14.1% | 231,696 | +2.3% | 1.57% | -25.5% |
Q1 2023 | $10,974,857 | +26.4% | 226,566 | -0.4% | 2.11% | +25.5% |
Q4 2022 | $8,683,331 | -27.6% | 227,491 | -4.8% | 1.68% | -28.9% |
Q3 2022 | $11,992,000 | +24.8% | 238,891 | -0.4% | 2.36% | +22.0% |
Q2 2022 | $9,611,000 | -2.6% | 239,908 | -9.3% | 1.94% | +10.6% |
Q1 2022 | $9,864,000 | -5.6% | 264,391 | +0.8% | 1.75% | +11.4% |
Q4 2021 | $10,447,000 | +11.3% | 262,291 | +4.0% | 1.57% | +101.3% |
Q3 2021 | $9,388,000 | -33.2% | 252,291 | -24.1% | 0.78% | -31.2% |
Q2 2021 | $14,046,000 | -41.2% | 332,291 | -34.2% | 1.14% | -37.3% |
Q1 2021 | $23,908,000 | -35.1% | 504,928 | -16.4% | 1.81% | -30.2% |
Q4 2020 | $36,861,000 | +17.8% | 603,978 | -9.8% | 2.60% | -3.5% |
Q3 2020 | $31,303,000 | +18.5% | 669,578 | +28.6% | 2.69% | +11.0% |
Q2 2020 | $26,419,000 | +98.2% | 520,667 | +74.2% | 2.42% | -5.2% |
Q1 2020 | $13,331,000 | -15.6% | 298,844 | -9.1% | 2.56% | +8.6% |
Q4 2019 | $15,789,000 | +23.8% | 328,738 | -12.9% | 2.36% | +7.0% |
Q3 2019 | $12,758,000 | -37.1% | 377,238 | -16.3% | 2.20% | -9.2% |
Q2 2019 | $20,279,000 | +16.3% | 450,638 | -2.7% | 2.42% | +15.6% |
Q1 2019 | $17,432,000 | +117.5% | 463,137 | +98.3% | 2.10% | +92.4% |
Q4 2018 | $8,015,000 | -16.5% | 233,536 | +14.3% | 1.09% | +7.0% |
Q3 2018 | $9,599,000 | +109.4% | 204,237 | +50.3% | 1.02% | +99.0% |
Q2 2018 | $4,583,000 | -61.3% | 135,884 | -69.0% | 0.51% | -60.6% |
Q1 2018 | $11,850,000 | +90.6% | 437,934 | +17.5% | 1.30% | +67.2% |
Q4 2017 | $6,216,000 | +82.2% | 372,634 | +118.5% | 0.78% | +76.6% |
Q3 2017 | $3,412,000 | +206.6% | 170,535 | +180.8% | 0.44% | +260.7% |
Q2 2017 | $1,113,000 | -67.8% | 60,735 | -82.7% | 0.12% | -69.7% |
Q1 2017 | $3,455,000 | +157.3% | 351,135 | +185.2% | 0.40% | +170.5% |
Q4 2016 | $1,343,000 | -87.7% | 123,135 | -84.2% | 0.15% | -86.1% |
Q3 2016 | $10,928,000 | +139.9% | 779,998 | +20.2% | 1.07% | +128.3% |
Q2 2016 | $4,556,000 | -72.9% | 648,976 | -75.2% | 0.47% | -42.3% |
Q1 2016 | $16,842,000 | -67.2% | 2,615,241 | +64.9% | 0.81% | -62.8% |
Q4 2015 | $51,395,000 | +178.8% | 1,586,258 | +129.8% | 2.19% | +159.6% |
Q3 2015 | $18,433,000 | -37.7% | 690,364 | +12.3% | 0.84% | -31.6% |
Q2 2015 | $29,588,000 | -35.4% | 614,742 | -18.4% | 1.23% | -29.1% |
Q1 2015 | $45,829,000 | -22.0% | 753,141 | -33.7% | 1.74% | -34.0% |
Q4 2014 | $58,766,000 | +1.0% | 1,135,130 | -14.2% | 2.64% | +7.6% |
Q3 2014 | $58,199,000 | +43.5% | 1,322,398 | -14.8% | 2.45% | +42.5% |
Q2 2014 | $40,550,000 | +63.7% | 1,551,274 | +63.7% | 1.72% | +68.6% |
Q1 2014 | $24,778,000 | +2438.7% | 947,902 | +1548.0% | 1.02% | +2326.2% |
Q4 2013 | $976,000 | -20.9% | 57,519 | 0.0% | 0.04% | -28.8% |
Q3 2013 | $1,234,000 | -4.5% | 57,519 | -33.2% | 0.06% | +55.3% |
Q2 2013 | $1,292,000 | – | 86,100 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 1,750,000 | $84,053,000 | 7.32% |
RTW INVESTMENTS, LP | 3,832,480 | $184,074,000 | 6.94% |
Burrage Capital Management LLC | 195,725 | $9,401,000 | 6.30% |
Asymmetry Capital Management, L.P. | 55,408 | $2,661,000 | 4.77% |
SECTORAL ASSET MANAGEMENT INC | 328,738 | $15,789,000 | 2.36% |
ARMISTICE CAPITAL, LLC | 758,000 | $36,407,000 | 2.10% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 114,000 | $5,470,000 | 1.97% |
Opaleye Management Inc. | 191,000 | $9,174,000 | 1.80% |
Sofinnova Investments, Inc. | 517,092 | $24,836,000 | 1.79% |
Chubb Ltd | 8,180 | $393,000 | 1.68% |